Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer | Nature Cancer https://t.co/5dNSc6YTwh
RT @NCIgenomics: Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests ne…
RT @NCIgenomics: Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests ne…
RT @NCIgenomics: Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests ne…
RT @NCIgenomics: Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests ne…
RT @NCIgenomics: Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests ne…
RT @ShainLab: I've been saying this for years... All those low mutation burden tumors that are wild type for every known cancer gene are ju…
RT @NCIgenomics: Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests ne…
I've been saying this for years... All those low mutation burden tumors that are wild type for every known cancer gene are just stromal cells
Great and useful paper, has to be taken into account
RT @NCIgenomics: Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests ne…
Study finds correlation of tumor mutation burden and tumor purity in whole-exome and targeted sequencing data, suggests new method to predict response to immune checkpoint blockade https://t.co/Ujbo9qeNnM https://t.co/lMAiPi5ulS
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @ValsamoA: Pure -tumor- tissue is the issue -or at least one of them- @velculescu @NoushinNiknafs @NatureCancer @hopkinskimmel https://t…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
RT @NCIgenomics: Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://…
Adjusting tumor mutation burden with tumor purity for better prediction of response to immune checkpoint blockade https://t.co/Ujbo9qeNnM
RT @ValsamoA: Pure -tumor- tissue is the issue -or at least one of them- @velculescu @NoushinNiknafs @NatureCancer @hopkinskimmel
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @AndresFCardonaZ: Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer https://t.co/G…
RT @NicoleKuderer: #OncoAlert Multimodal genomic features suggested to predict outcome of immune checkpoint blockade in non-small-cell lung…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @AndresFCardonaZ: Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer https://t.co/G…
'Through analysis of whole-exome and targeted sequence data from 5,449 tumors, we found a significant correlation between tumor mutation burden (TMB) and tumor purity, suggesting that low tumor purity tumors are likely to have inaccurate TMB estimates.' h
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @NicoleKuderer: #OncoAlert Multimodal genomic features suggested to predict outcome of immune checkpoint blockade in non-small-cell lung…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @NicoleKuderer: #OncoAlert Multimodal genomic features suggested to predict outcome of immune checkpoint blockade in non-small-cell lung…
RT @AndresFCardonaZ: Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer https://t.co/G…
New study on TMB. Not sure how all these prediction algorithms will play out by the end. Although it is a prediction for ICI, neoantigen prediction seems not heavily weighted in formula. Even so, it is extremely difficult to predict epitope and immune resp
RT @NicoleKuderer: #OncoAlert Multimodal genomic features suggested to predict outcome of immune checkpoint blockade in non-small-cell lung…
RT @NicoleKuderer: #OncoAlert Multimodal genomic features suggested to predict outcome of immune checkpoint blockade in non-small-cell lung…
#OncoAlert Multimodal genomic features suggested to predict outcome of immune checkpoint blockade in non-small-cell lung cancer | Nature Cancer #IO #immunotherapy https://t.co/YxXDM9Czkx
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer https://t.co/GNFhHv74oB
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently published in Nature Cancer may help identify patients that benefit most from immune checkpoint blockade. https://t.co/vnIoeBr0Ta #stock…h
"Deep Learning" by damn smart humans reveal genomic features of response to immune checkpoint blockade therapy. Tumor mutation burden, mutation signatures, HLA genotype, clonality, and RTK mutations all inform response landscape. "Strong Work".
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @ValsamoA: Pure -tumor- tissue is the issue -or at least one of them- @velculescu @NoushinNiknafs @NatureCancer @hopkinskimmel
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @ValsamoA: Pure -tumor- tissue is the issue -or at least one of them- @velculescu @NoushinNiknafs @NatureCancer @hopkinskimmel
RT @ValsamoA: Pure -tumor- tissue is the issue -or at least one of them- @velculescu @NoushinNiknafs @NatureCancer @hopkinskimmel https://t…
Pure -tumor- tissue is the issue -or at least one of them- @velculescu @NoushinNiknafs @NatureCancer @hopkinskimmel
RT @jjdmochon: @isliquidbiopsy @ChristianRolfo @MCristofanill @MJOSESERRANO19 @jlorentegrx
Towards Precision Oncology
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @velculescu: Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently publis…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer: https://t.co/2CFjm84ATp
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…